Immunic initiated with a Buy at Stifel

Stifel initiated coverage of Immunic (IMUX) with a Buy rating and $2.50 price target The cites a belief that vidoflimus calcium has a high probability-of-success in Phase 3 RMS studies with data due by year-end and says it views VidoCa as having a differentiated safety profile that should be “enough to garner meaningful uptake in the crowded MS market.”